Evidence map›Paper›PMID 39570305›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

What can the eye see with melanopsin?

Thomas W Nugent, Andrew J Zele

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas W NugentCentre for Vision and Eye Research, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0009-0006-9784-6468
Andrew J ZeleCentre for Vision and Eye Research, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0000-0003-0291-9929

Funding

Department of Education and Training | Australian Research Council (ARC) ARC-FT180100458
6 · The paper itself

Abstract

A subpopulation of human retinal ganglion cells contains the melanopsin photopigment, allowing them to act as a fifth photoreceptor class. These ganglion cells project to the visual cortex, but to reveal its intrinsic contribution to conscious vision is technically challenging as it requires melanopsin to be separated from the responses originating in the rods and three cone classes. Using a display engineered to isolate the melanopic visual response, we show that it detects lowpass spatial (≤0.35 cycles per degree) and temporal image content (≤1 Hz) but cannot reconstruct the stimulus form necessary for object recognition. We demonstrate that a model of the spatially diffuse intrinsically-photosensitive retinal ganglion cells' sampling structure is predictive of the measured image reconstruction limits of melanopic spatial vision. Separately, we find that under five-photoreceptor silent substitution conditions, rod pathways alone can support form vision in bright lighting when typically thought to be in saturation. Form vision that is absent from melanopsin can be only perceived in mixtures of both melanopsin and rod signals because it is the rod pathway that sees the form. Our findings show that melanopsin's unique tuning to the diffuse and slow-changing elements in the world provides a stabilized reference point for vision.

Indexed as

Retinal Ganglion CellsRod OpsinsHumansMelanopsinPhotic StimulationRetinal Cone Photoreceptor CellsRetinal Rod Photoreceptor CellsVision, OcularMelanopsinRod OpsinshumanipRGCsmelanopsinsilent substitutionvision

Identifiers

PMID39570305
PMCPMC11621463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.